Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs and FX are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
61% of retail CFD accounts lose money. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more at https://etoro.tw/44JRWLY
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
AstraZeneca (LON:AZN) has unveiled plans to inject $50 billion into its U.S. operations by 2030, signaling a major commitment to manufacturing and research within the American market. The move aims to propel the pharmaceutical giant towards its ambitious $80 billion revenue target, with the U.S. expected to contribute 50% of this total.
The firm’s landmark $50 billion investment in the United States aims to bolster domestic manufacturing capabilities and strengthen R&D infrastructure across multiple states, supporting the company’s revenue growth ambitions and creating thousands of highly skilled jobs.
At the heart of this investment is a proposed multi-billion dollar drug substance manufacturing facility in Virginia. This will be AstraZeneca’s most substantial single investment in a facility to date. The plant will focus on producing treatments for chronic diseases, including innovative therapies for weight management and metabolic disorders.
Sponsored content
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The Virginia facility will produce drug substances for AstraZeneca’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products. This state-of-the-art center will produce small molecules, peptides, and oligonucleotides.
The $50 billion will also fund expansion across AstraZeneca’s U.S. footprint. This includes R&D facilities in Maryland and Massachusetts, cell therapy manufacturing in Maryland and California, and continuous manufacturing expansion in Indiana and Texas, plus new clinical trial sites.
“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.” Pascal Soriot, AstraZeneca CEO
U.S. Secretary of Commerce Howard Lutnick lauded the investment as a step towards reducing reliance on foreign pharmaceutical supplies. Governor Glenn Youngkin of Virginia echoed this sentiment, highlighting the creation of high-skilled jobs and the strengthening of the domestic supply chain.
While the market is largely flat on AstraZeneca’s massive U.S. investment, a devil’s advocate perspective suggests potential pitfalls. The sheer scale of the investment could strain resources and divert focus from other critical areas. Moreover, relying heavily on the U.S. market exposes AstraZeneca to specific political and economic risks, including potential drug pricing reforms and changes in healthcare policy.
AZN.LSE
AstraZeneca’s next earnings report, scheduled for July 29, will provide crucial insights into the company’s financial performance and the early impact of its strategic initiatives. Analysts project earnings per share (EPS) of $1.11 for the upcoming quarter, representing a 7.77% increase from the same period last year.
The AZN share price has been largely unmoved by the news, with the latest price of 10,238p on the LSE almost exactly where it closed off Monday’s session.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.
Stay ahead of the markets
Sign up to our free Morning Markets email, every weekday before the open.
Stay ahead of the markets
Morning Markets
Weekdays
FTSE, overnight moves and what matters before the open.
Show personalised advertising and content, and measure how adverts and content perform
Learn about our audience and develop and improve our services
Learn more
Advertising pays for our free market news, analysis and trading tools.
If you accept, we and our partners may also match and combine data from other sources, link your devices, and identify your device from its characteristics, precise location or by actively scanning it. Some partners rely on legitimate interest rather than consent for certain purposes; you can object in the full list.
You can reject, or choose which purposes to allow under Manage options. Your choice is kept for this browser and you can change it at any time. See every purpose and partner
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner
We and our advertising partners use cookies to show relevant advertising and measure its performance. You can opt out of the sale or sharing of your personal information, and of personalised advertising, at any time using the link below.
Necessary
Always active
Needed to run AskTraders and to remember your choice here. Always on.
Preferences
Remembers choices you make on AskTraders, such as display settings.
Analytics
Lets us count visits and see which pages are useful, using tools such as Google Analytics.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Advertising and personalisation
Lets us and our advertising partners show personalised adverts and content, measure them and learn about our audience, and lets us offer web push notifications. See every purpose and partner
